Combination of Yondelis (ET-743) and oxaliplatin in experimental ovarian cancer.

被引：0
|
作者：
Erba, E
Colombo, T
Ubezio, P
Ferrarese, L
Matera, G
Falcioni, C
Faircloth, G
Jimeno, J
D'Incalci, M
机构：
[1] IM Mario Negri, Milan, Italy
[2] PharmaMar R&D, Boston, MA USA
[3] PharmaMar R&D, Madrid, Spain
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6264S / 6264S
页数：1
相关论文
共 50 条
  • [1] Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer
    Beumer, Jan H.
    Rademaker-Lakhai, Jeany M.
    Rosing, Hilde
    Hillebrand, Michel J. X.
    Bosch, Tessa M.
    Lopez-Lazaro, Luis
    Schellens, Jan H. M.
    Beijnen, Jos H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (06) : 825 - 837
  • [2] Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer
    Jan H. Beumer
    Jeany M. Rademaker-Lakhai
    Hilde Rosing
    Michel J. X. Hillebrand
    Tessa M. Bosch
    Luis Lopez-Lazaro
    Jan H. M. Schellens
    Jos H. Beijnen
    Cancer Chemotherapy and Pharmacology, 2007, 59 : 825 - 837
  • [3] Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma
    Skorupa, Amy
    Beldner, Matthew
    Kraft, Andrew
    Montero, Alberto J.
    CANCER BIOLOGY & THERAPY, 2007, 6 (07) : 1015 - 1017
  • [4] Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma
    Tewari, Devansu
    Saffari, Bahman
    Cowan, Carol
    Wallick, Anita C.
    Koontz, M. Zach
    Monk, Bradley J.
    GYNECOLOGIC ONCOLOGY, 2006, 102 (03) : 421 - 424
  • [5] Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis®) in cancer patients
    Jose Perez-Ruixo, Juan
    Zannikos, Peter
    Hirankarn, Sarapee
    Stuyckens, Kim
    Ludwig, Elizabeth A.
    Soto-Matos, Arturo
    Lopez-Lazaro, Luis
    Owen, Joel S.
    CLINICAL PHARMACOKINETICS, 2007, 46 (10) : 867 - 884
  • [6] Trabectedin (Yondelis™, formerly ET-743), a mass balance study in patients with advanced cancer
    Beumer, JH
    Rademaker-Lakhai, JM
    Rosing, H
    Lopez-Lazaro, L
    Beijnen, JH
    Schellens, JHM
    INVESTIGATIONAL NEW DRUGS, 2005, 23 (05) : 429 - 436
  • [7] Population pharmacokinetics of trabectedin (ET-743) in subjects with cancer.
    Ruixo, J. J. Perez
    Zannikos, P.
    Hirankarn, S.
    Stuyckens, K.
    Liolios, K.
    Soto-Matos, A.
    Lopez-Lazaro, L.
    Pico, C.
    Yver, A.
    Owen, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 86S - 86S
  • [8] Population Pharmacokinetic Meta-Analysis of Trabectedin (ET-743, Yondelis®) in Cancer Patients
    Juan Jose Perez-Ruixo
    Peter Zannikos
    Sarapee Hirankam
    Kim Stuyckens
    Elizabeth A. Ludwig
    Arturo Soto-Matos
    Luis Lopez-Lazaro
    Joel S. Owen
    Clinical Pharmacokinetics, 2007, 46 : 867 - 884
  • [9] An interspecies comparison of the metabolism of the anticancer agent Yondelis™ (Trabectedin, ET-743)
    Vermeir, M
    Hendrickx, J
    Hurkmans, R
    Van Houdt, J
    Zwijsen, C
    Bode, W
    Aviles, P
    Manzanares, I
    Mannens, G
    Meuldermans, W
    De Coster, R
    CYTOCHROMES P450, BIOCHEMISTRY, BIOPHYSICS AND DRUG METABOLISM, 2003, : 327 - 331
  • [10] Yondelis® (trabectedin, ET-743):: the development of an anticancer agent of marine origin
    van Kesteren, C
    de Vooght, MMM
    López-Lázaro, L
    Mathôt, RAA
    Schellens, JHM
    Jimeno, JM
    Beijnen, JH
    ANTI-CANCER DRUGS, 2003, 14 (07) : 487 - 502
12345